Comparison: Retatrutide vs Tirzepatide (Triple or Dual Agonist)
Retatrutide and tirzepatide are almost always mentioned together. The difference between them is how many receptors each molecule recognizes: tirzepatide fits two, retatrutide three. Think of each receptor as a lock and the molecule as a key: tirzepatide is a key cut to open two locks at the same time; retatrutide carries a third cut that opens one more lock. This is research-use-only (RUO) content: it does not cover human use, dosing, protocols or effects.
Two receptors versus three
Tirzepatide is a synthetic 39-amino-acid peptide that opens two locks: the GIP receptor and the GLP-1 receptor — two gut hormones the body releases when you eat, both telling the pancreas to produce insulin. That is why it is described as a dual agonist. Its design starts from the GIP sequence and carries an added fatty chain that keeps it active longer.
Retatrutide keeps those two entries and adds a third: the glucagon receptor. Hence the triple agonist label. In the paper that first described the molecule, published in Cell Metabolism in 2022, it was characterized as active at all three locks, with balanced activity at the glucagon and GLP-1 receptors and stronger activity at the GIP receptor (see Sources).
They are not versions of the same molecule: they are two distinct sequences with distinct receptor profiles. Any other comparison, such as which one is preferable or what results each produces, leaves research territory and enters medical guidance, which is not covered here.
"Dual agonist" does not mean even activity
A molecule opening two locks does not mean it opens them with the same force. A pharmacology study published in JCI Insight in 2020 examined this in detail and described tirzepatide as an imbalanced dual agonist: it behaves like native GIP at the GIP lock, and only partially at the GLP-1 lock (see Sources).
For laboratory work, that detail matters more than the label. "Dual" and "triple" count how many locks a molecule recognizes, not with what force it opens them or through which signaling pathway. Two compounds can share a label and behave differently in an assay.
What changes when verifying each batch
In the lab, the procedure to review a batch is the same for both: what changes is the reference the result is compared against. Each molecule has its own mass and its own sequence, so the Certificate of Analysis for a batch of retatrutide and one for a batch of tirzepatide are read the same way but compared against different references.
The two data points to look for are the same in both cases. Identity is confirmed by weighing the molecule with mass spectrometry: the measured weight has to hit the correct value for that sequence and not for the other one. Purity is measured by high-performance liquid chromatography (HPLC), which separates what is inside the vial and calculates what percentage of the total corresponds to the main peak. For detail on how to interpret that number, what HPLC purity is explains it, and how to read a COA walks through the full document.
Identity and purity are separate questions, and they get confused often. A sample can be 99% pure of something that isn't the molecule you ordered. That is why the two tests are read together, and why the COA has to match the batch you receive rather than a generic catalog reference.
Reconstitution: same math, different vial
Both are distributed lyophilized, as a dry powder, because that is the state in which they travel and store best. The concentration math when you reconstitute is the same for both: it depends on the milligrams in the vial and the volume of liquid you add, not on how many locks the peptide opens. The peptide calculator handles that conversion. If this is your first time, the step-by-step guide covers the procedure and bacteriostatic vs. sterile water clarifies which liquid applies in each case.
Choosing between them for an assay
The choice is an experimental-design decision, not a product-quality comparison. If the work centers on the two classic incretin locks (GIP and GLP-1), tirzepatide is the best-characterized two-entry molecule. If the design also needs to include the glucagon lock, that third entry is present only in retatrutide. There is no "better one": there is one that matches the receptors your protocol covers.
What applies equally to both is the verification standard. Without a per-batch COA carrying HPLC purity and mass-spectrometry identity, the label on the vial is an unsupported claim, no matter how many receptors the molecule is said to activate. To see both alongside the rest of the catalog, the comparison tool puts them side by side, and research peptides gathers the full category. If you already know which one matches your protocol, you can buy retatrutide in Mexico or buy tirzepatide directly from the catalog.
Sources
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234–1247.e9. PubMed 35985340
- Willard FS, Douros JD, Gabe MBN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PubMed 32730231 · doi:10.1172/jci.insight.140532